Information

Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

You are browsing as a GUEST
Title of the item:

Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma

Title :
Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma
Authors :
Miyahara, K
Nouso, K
Morimoto, Y
Takeuchi, Y
Hagihara, H
Kuwaki, K
Onishi, H
Ikeda, F
Miyake, Y
Nakamura, S
Shiraha, H
Takaki, A
Honda, M
Kaneko, S
Sato, T
Sato, S
Obi, S
Iwadou, S
Kobayashi, Y
Takaguchi, K
Kariyama, K
Takuma, Y
Takabatake, H
Yamamoto, K
Show more
Subject Terms :
Clinical Study
angiopoietin-2
cytokine
sorafenib
angiogenesis
hepatocellular carcinoma
Source :
British Journal of Cancer
Publisher :
Nature Publishing Group, 2013.
Publication Year :
2013
Original Identifier :
pmc: PMC3798958
pmid: 24045661
Language :
English
ISSN :
1532-1827
0007-0920
DOI :
10.1038/bjc.2013.554
Background: We previously reported that expressions of the pro-angiogenic cytokines angiopoietin-2 (Ang-2), follistatin, granulocyte colony-stimulating factor, hepatocyte growth factor, leptin, platelet-derived growth factor-BB, platelet endothelial cell adhesion molecule-1, and vascular endothelial growth factor were associated with the response to sorafenib in patients with advanced hepatocellular carcinoma (HCC). The aim of the present study is to examine the same relationship in a larger cohort. Methods: In the current retrospective cohort study, we measured serum levels of the eightcytokines in 120 consecutive HCC patients who were treated with sorafenib. We evaluated the effects of increased expression of serum cytokines on progression-free survival (PFS) and overall survival (OS). Results: Elevated expression of Ang-2 correlated both with significantly shorter PFS (hazard ratio (HR), 1.84; 95% confidence interval (CI), 1.21–2.81), and OS (HR, 1.95; 95% CI, 1.21–3.17). Patients with more than three cytokines expressed above the median similarly had significantly shorter PFS (HR, 1.98; 95% CI, 1.30–3.06) and OS (HR, 1.94; 95% CI, 1.19–3.22). Differences in OS were evident in cases with the evidence of macroscopic vascular invasion or extrahepatic metastasis. Conclusion: High expression of Ang-2 or more than cytokines in serum is associated with poor PFS and OS in HCC patients treated with sorafenib.

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.